This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

Table 4.5 Epigenetic Therapies and Technologies: Market Shares by Country, 2011-2023

Table 4.6 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.7 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.8 European Epigenetic Therapies and Technologies Market by Country, 2011

Table 4.9 Selected Epigenetic Companies Headquartered in the EU, 2012

Table 4.10 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Leading Country, 2011-2023

Table 4.11 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.12 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.13 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.14 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 5.1 Epigenetic Therapies Submarket: Drug Revenue Shares, 2011-2023

Table 5.2 Vidaza: Revenue, 2004-2011

Table 5.3 Vidaza: Revenue by Region, H1 2011-2012

Table 5.4 Vidaza: Revenue Forecast, 2011-2023

Table 5.5 Vidaza: Drivers and Restraints, 2013-2023

Table 5.6 Dacogen: Revenue and Royalty Revenue, 2006-2011

Table 5.7 Dacogen: Phase III Clinical Trials, 2012

Table 5.8 Dacogen: Drivers and Restraints, 2013-2023

Table 5.9 Dacogen: Revenue Forecast, 2011-2023

Table 5.10 Zolinza: Drivers and Restraints, 2013-2023

Table 5.11 Zolinza: Revenue Forecast, 2011-2023

Table 5.12 Istodax: Revenue, 2010-2011

Table 5.13 CTCL and PTCL Prevalence by Region

Table 5.14 Istodax: Drivers and Restraints, 2013-2023

Table 5.15 Istodax: Revenue Forecast, 2011-2023

Table 5.16 Selected HDAC Inhibitors in Development, 2012

Table 5.17 NCI Sponsored Trials of Belinostat, 2012

Table 5.18 Belinostat: Revenue Forecast, 2014-2023

Table 5.19 Faridak: Revenue Forecast, 2014-2023

Table 5.20 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012

Table 5.21 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2012

Table 5.22 Selected MiRNA Therapy Pipeline, 2012

Table 5.23 CellCentric's Research Institution Affiliations, 2012

Table 5.24 IkerChem Epigenetic Pipeline, 2012

Table 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012

9 of 12

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs